Open AccessChanges in oral antidiabetic prescriptions and improved glycemic control during the years 2002–2011 in J apan ( JDDM 32)
Author(s) -
Oishi Mariko,
Yamazaki Katsuya,
Okuguchi Fuminobu,
Sugimoto Hidekatsu,
Kanatsuka Azuma,
Kashiwagi Atsunori
Publication year - 2014
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.12183
Subject(s) - medicine , glycemic , glycated hemoglobin , diabetes mellitus , medical prescription , glycated haemoglobin , combination therapy , type 2 diabetes , pharmacology , endocrinology
Aims/Introduction Six kinds of oral antidiabetic drugs ( OAD s), including the new dipeptidyl peptidase 4 ( DPP ‐4) inhibitors, are available. The present study aimed to define trends within the prescribing patterns of OAD s, as well as changes in glycemic control in Japan over a 10‐year period from 2002 to 2011. Materials and Methods We carried out a cross‐sectional study using data of type 2 diabetes mellitus patients from 24 clinics for 2002, 2005, 2008 and 2011. OAD use was analyzed combined with clinical data. Results Sulfonylureas ( SU s) were the most commonly used OAD , but their use for monotherapy markedly decreased over the study period. Biguanides ( BG s) were the second most commonly used OAD , and their prescribing rate increased both for mono‐ and combination therapy. DPP ‐4 inhibitors ( DPP ‐4I), released in 2009, were the third most commonly prescribed OAD in 2011 both for mono‐ and combination therapy. Among combination therapies, two OAD s were mostly prescribed, but the use of three OAD s and four OAD s in 2011 was two‐ and 14.8‐fold those in 2002. These trends were accompanied by an improvement in average glycated hemoglobin from 7.5 ± 1.2% in 2002 to 7.1 ± 0.9% in 2011. Conclusions The OAD prescribing trend has moved away from monotherapy with SU s and toward combination therapies to achieve better glycemic control. Increased use of BG s and DPP ‐4I was predominant in 2011. These trends were accompanied by an improvement of the glycated hemoglobin level.